NCT00904787View on ClinicalTrials.gov

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

May 31, 2011

Conditions
Relapsed or Refractory Hematological Malignancies
Interventions
DRUG

ENMD-2076

capsule, dose escalation, taken orally, daily in 28 day cycles

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY